Scilex Holding Company announced the publication of a study in Pain Medicine News revealing that patients treated with ZTlido® (lidocaine topical system 1.8%) showed a greater reduction in opioid use ...

More patients treated with ZTlido ® saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%). Of all study patients reporting a decrease ...

The non-aqueous adhesive patch requires 36mg per topical system to achieve the same therapeutic dose as Lidoderm (lidocaine 5%) which contains 700mg per patch. Scilex, a subsidiary of Sorrento, ...

SAN DIEGO, Sept. 7, 2018 /PRNewswire/ -- Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced data showing ZTlido™ (lidocaine ...

Scilex Holding Company is engaged in the acquisition, development, and commercialization of non-opioid products to address acute and chronic pain. The company has a portfolio that includes ...

ZTlido ® gross sales grew from approximately $1 million in March to $2.4 million in April and $3.3 million in May SP-102 pivotal phase 3 trial remains on track for completion in H1 2020 ZTlido ® 5.4% ...

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido® ...